Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 63, Number 11, December 14, 2004
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murinson, B. B.
Right arrow Articles by Solimena, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murinson, B. B.
Right arrow Articles by Solimena, M.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Stiff person syndrome
Right arrowRelated Articles
NEUROLOGY 2004;63:2146-2148
© 2004 American Academy of Neurology
Brief Communications

Markedly elevated GAD antibodies in SPS

Effects of age and illness duration

B. B. Murinson, MD, PhD, M. Butler, PhD, K. Marfurt, BS, S. Gleason, PhD, P. De Camilli, MD and M. Solimena, MD, PhD

From the Department of Neurology (Dr. Murinson), Johns Hopkins School of Medicine, Baltimore, MD; Boyer Center for Molecular Medicine (Drs. Butler and De Camilli) and Howard Hughes Medical Institute (Dr. De Camilli), Yale University School of Medicine, New Haven, CT; Bayer Diagnostics Division (Dr. Gleason, K. Marfurt), Elkhart, IN; and Faculty of Medicine (Dr. Solimena), Medizinisch Theoretisches Zentrum, Faculty of Medicine, TU-Dresden, Germany.

Address correspondence and reprint requests to Dr. B.B. Murinson, 509 Pathology, 600 N. Wolfe St., Baltimore, MD 21287; e-mail: Bmurins1{at}jhmi.edu

Five hundred seventy-six patients with suspected stiff-person syndrome (SPS) underwent immunocytochemistry (ICC). Of these, 286 underwent radioimmunoassay (RIA) for glutamic acid decarboxylase (GAD) antibodies; 116 were GAD antibody positive by one or both tests. Ninety-six percent of those positive by ICC had RIA values several standard deviations above normal. RIA did not correlate with age or illness duration. Marked elevations of RIA for GAD antibodies were characteristic of ICC-confirmed SPS, and modest elevations were not.

Received March 4, 2004. Accepted in final form August 10, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 14 issue to find the title link for this article.

See also page 1999

K. Marfurt and Dr. Gleason are employees of Bayer Corporation. Drs. Solimena and De Camilli hold US patent no. 5,512,447 on the detection of glutamic acid decarboxylase autoantibodies.


Related Articles

December 14 Highlights
Neurology 2004 63: 1992-1993. [Full Text] [PDF]

GAD antibodies in stiff-person syndrome
Thashi Chang and Bethan Lang
Neurology 2004 63: 1999-2000. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NeurologyHome page
B. B. Murinson and J. B. Guarnaccia
Stiff-person syndrome with amphiphysin antibodies: Distinctive features of a rare disease
Neurology, December 9, 2008; 71(24): 1955 - 1958.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Chang and B. Lang
GAD antibodies in stiff-person syndrome
Neurology, December 14, 2004; 63(11): 1999 - 2000.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.